How a brain medicine gets inside cells

Original Title

Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

Scientists wanted to see how a medicine called cyclocreatine gets into brain-related cells. They tested it in lab-grown cells and cells from patients who can't move creatine into their brains.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

Cyclocreatine uses the same transporter as creatine despite being a synthetic analog.

Many drug analogs are designed to bypass defective transporters, so finding that cyclocreatine still depends on SLC6A8 is unexpected—especially since the goal was to treat SLC6A8 deficiency.

Practical Takeaways

Cyclocreatine may be a candidate for treating cerebral creatine deficiency syndromes—if the patient has some remaining creatine transporter function.

low confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.